| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 58 | 2026 | 705 | 12.330 |
Why?
|
| Renal Insufficiency, Chronic | 52 | 2026 | 853 | 7.260 |
Why?
|
| Alberta | 58 | 2026 | 64 | 3.340 |
Why?
|
| Glomerular Filtration Rate | 39 | 2026 | 566 | 3.290 |
Why?
|
| Acute Coronary Syndrome | 9 | 2026 | 235 | 2.980 |
Why?
|
| Kidney Failure, Chronic | 21 | 2026 | 934 | 2.680 |
Why?
|
| Contrast Media | 9 | 2022 | 474 | 2.460 |
Why?
|
| Percutaneous Coronary Intervention | 9 | 2024 | 299 | 2.310 |
Why?
|
| Risk Assessment | 31 | 2026 | 3711 | 2.300 |
Why?
|
| Renal Replacement Therapy | 11 | 2026 | 172 | 2.150 |
Why?
|
| Kidney | 19 | 2026 | 1282 | 2.100 |
Why?
|
| Renal Dialysis | 27 | 2026 | 951 | 2.080 |
Why?
|
| Coronary Angiography | 9 | 2026 | 450 | 2.000 |
Why?
|
| Decision Support Systems, Clinical | 3 | 2022 | 205 | 1.640 |
Why?
|
| Postoperative Complications | 12 | 2025 | 3147 | 1.600 |
Why?
|
| Creatinine | 18 | 2024 | 398 | 1.480 |
Why?
|
| Cardiac Catheterization | 7 | 2020 | 630 | 1.420 |
Why?
|
| Aged | 90 | 2026 | 21025 | 1.410 |
Why?
|
| Coronary Artery Disease | 11 | 2026 | 887 | 1.400 |
Why?
|
| Decision Support Techniques | 4 | 2026 | 293 | 1.380 |
Why?
|
| Middle Aged | 95 | 2026 | 28601 | 1.320 |
Why?
|
| Cohort Studies | 39 | 2026 | 5063 | 1.300 |
Why?
|
| Surgical Procedures, Operative | 5 | 2021 | 225 | 1.230 |
Why?
|
| Humans | 173 | 2026 | 131163 | 1.210 |
Why?
|
| Male | 112 | 2026 | 64957 | 1.150 |
Why?
|
| Risk Factors | 45 | 2026 | 11074 | 1.150 |
Why?
|
| Cardiovascular Diseases | 16 | 2025 | 2121 | 1.140 |
Why?
|
| Female | 115 | 2026 | 70963 | 1.120 |
Why?
|
| Renal Insufficiency | 8 | 2025 | 259 | 1.110 |
Why?
|
| Aged, 80 and over | 42 | 2026 | 6797 | 1.070 |
Why?
|
| Nephrology | 4 | 2022 | 162 | 1.070 |
Why?
|
| Electronic Health Records | 4 | 2025 | 844 | 1.050 |
Why?
|
| Hospitalization | 21 | 2020 | 1950 | 1.040 |
Why?
|
| Kidney Diseases | 9 | 2024 | 477 | 1.000 |
Why?
|
| Prognosis | 24 | 2026 | 4886 | 0.970 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2026 | 20 | 0.930 |
Why?
|
| Incidence | 24 | 2025 | 3360 | 0.930 |
Why?
|
| Practice Guidelines as Topic | 5 | 2021 | 1295 | 0.920 |
Why?
|
| Quality of Life | 14 | 2026 | 2082 | 0.890 |
Why?
|
| Disease Progression | 13 | 2026 | 2200 | 0.840 |
Why?
|
| Diabetes Mellitus | 8 | 2025 | 889 | 0.830 |
Why?
|
| Models, Biological | 3 | 2019 | 1371 | 0.820 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2026 | 214 | 0.790 |
Why?
|
| Cause of Death | 7 | 2020 | 506 | 0.790 |
Why?
|
| Quality Indicators, Health Care | 3 | 2026 | 240 | 0.760 |
Why?
|
| Proteinuria | 6 | 2018 | 109 | 0.750 |
Why?
|
| Delivery of Health Care | 3 | 2018 | 689 | 0.750 |
Why?
|
| Nurse Practitioners | 1 | 2023 | 50 | 0.750 |
Why?
|
| Health Care Costs | 5 | 2022 | 407 | 0.740 |
Why?
|
| Albuminuria | 8 | 2020 | 107 | 0.740 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2020 | 1168 | 0.730 |
Why?
|
| Patient Reported Outcome Measures | 5 | 2025 | 222 | 0.730 |
Why?
|
| Medical Audit | 1 | 2022 | 98 | 0.710 |
Why?
|
| Patient Readmission | 4 | 2026 | 442 | 0.710 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 292 | 0.700 |
Why?
|
| Canada | 18 | 2026 | 327 | 0.700 |
Why?
|
| Feedback | 1 | 2022 | 144 | 0.690 |
Why?
|
| Angina Pectoris | 4 | 2023 | 56 | 0.690 |
Why?
|
| Adult | 57 | 2026 | 31282 | 0.680 |
Why?
|
| Ileostomy | 1 | 2021 | 31 | 0.680 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2023 | 744 | 0.650 |
Why?
|
| Arteriovenous Shunt, Surgical | 6 | 2017 | 86 | 0.650 |
Why?
|
| Myocardial Infarction | 7 | 2022 | 999 | 0.640 |
Why?
|
| Continuous Positive Airway Pressure | 3 | 2016 | 63 | 0.640 |
Why?
|
| Sleep Apnea Syndromes | 3 | 2016 | 96 | 0.630 |
Why?
|
| Diuretics | 1 | 2021 | 159 | 0.620 |
Why?
|
| Retrospective Studies | 41 | 2025 | 17753 | 0.620 |
Why?
|
| Angiotensin Receptor Antagonists | 5 | 2026 | 133 | 0.620 |
Why?
|
| Self-Management | 4 | 2025 | 120 | 0.620 |
Why?
|
| Hypoxia | 3 | 2016 | 247 | 0.620 |
Why?
|
| Comorbidity | 11 | 2018 | 1595 | 0.590 |
Why?
|
| Radiography, Interventional | 1 | 2019 | 79 | 0.590 |
Why?
|
| Kidney Transplantation | 4 | 2026 | 558 | 0.580 |
Why?
|
| Disease Management | 2 | 2020 | 558 | 0.570 |
Why?
|
| Coronary Artery Bypass | 4 | 2024 | 515 | 0.570 |
Why?
|
| Patient Participation | 4 | 2026 | 254 | 0.560 |
Why?
|
| Models, Theoretical | 3 | 2019 | 362 | 0.530 |
Why?
|
| Telemedicine | 4 | 2025 | 526 | 0.530 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 325 | 0.520 |
Why?
|
| Aftercare | 2 | 2023 | 157 | 0.520 |
Why?
|
| Communication | 2 | 2020 | 543 | 0.500 |
Why?
|
| Acute Disease | 4 | 2024 | 1153 | 0.500 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2024 | 789 | 0.500 |
Why?
|
| Time Factors | 19 | 2026 | 6196 | 0.490 |
Why?
|
| Urination | 1 | 2016 | 23 | 0.490 |
Why?
|
| Epidural Abscess | 1 | 2016 | 11 | 0.490 |
Why?
|
| Severity of Illness Index | 17 | 2025 | 3061 | 0.490 |
Why?
|
| Peptide Fragments | 1 | 2020 | 687 | 0.490 |
Why?
|
| Intensive Care Units | 7 | 2025 | 526 | 0.480 |
Why?
|
| Patient Discharge | 5 | 2026 | 514 | 0.480 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 228 | 0.460 |
Why?
|
| Kidney Function Tests | 8 | 2019 | 135 | 0.460 |
Why?
|
| Qualitative Research | 8 | 2026 | 730 | 0.450 |
Why?
|
| Mortality | 5 | 2020 | 264 | 0.440 |
Why?
|
| Catheterization, Central Venous | 3 | 2017 | 143 | 0.440 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2026 | 1267 | 0.440 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 350 | 0.440 |
Why?
|
| Mandibular Advancement | 1 | 2014 | 5 | 0.440 |
Why?
|
| Atrial Fibrillation | 5 | 2023 | 738 | 0.430 |
Why?
|
| Length of Stay | 6 | 2025 | 1421 | 0.420 |
Why?
|
| Predictive Value of Tests | 9 | 2026 | 2304 | 0.410 |
Why?
|
| Polyuria | 1 | 2013 | 9 | 0.390 |
Why?
|
| Patient Admission | 4 | 2020 | 185 | 0.380 |
Why?
|
| Renal Artery Obstruction | 1 | 2013 | 40 | 0.380 |
Why?
|
| Critical Illness | 4 | 2026 | 630 | 0.380 |
Why?
|
| Obesity | 4 | 2019 | 2426 | 0.370 |
Why?
|
| Follow-Up Studies | 16 | 2020 | 5196 | 0.370 |
Why?
|
| Veterans Health | 1 | 2014 | 170 | 0.370 |
Why?
|
| Hyponatremia | 1 | 2013 | 73 | 0.360 |
Why?
|
| Health Status | 4 | 2026 | 378 | 0.360 |
Why?
|
| Critical Care | 2 | 2020 | 686 | 0.360 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 707 | 0.350 |
Why?
|
| Hypertension | 3 | 2015 | 1356 | 0.350 |
Why?
|
| Focus Groups | 5 | 2026 | 239 | 0.340 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 205 | 0.340 |
Why?
|
| Ischemic Attack, Transient | 3 | 2023 | 58 | 0.340 |
Why?
|
| Health Personnel | 5 | 2025 | 541 | 0.340 |
Why?
|
| Treatment Outcome | 17 | 2024 | 12936 | 0.330 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2014 | 245 | 0.330 |
Why?
|
| Societies, Medical | 2 | 2018 | 798 | 0.300 |
Why?
|
| Conservative Treatment | 2 | 2023 | 46 | 0.300 |
Why?
|
| Reproducibility of Results | 5 | 2026 | 2904 | 0.300 |
Why?
|
| Registries | 8 | 2025 | 1634 | 0.300 |
Why?
|
| Heart Failure | 9 | 2026 | 2332 | 0.300 |
Why?
|
| Risk Adjustment | 2 | 2021 | 55 | 0.290 |
Why?
|
| Depression | 3 | 2024 | 1320 | 0.280 |
Why?
|
| Environmental Monitoring | 2 | 2026 | 99 | 0.270 |
Why?
|
| British Columbia | 2 | 2026 | 10 | 0.270 |
Why?
|
| Forecasting | 2 | 2021 | 351 | 0.260 |
Why?
|
| Chronic Disease | 6 | 2023 | 1246 | 0.260 |
Why?
|
| Peritoneal Dialysis | 2 | 2022 | 133 | 0.260 |
Why?
|
| Coronary Disease | 3 | 2019 | 624 | 0.260 |
Why?
|
| Warfarin | 3 | 2023 | 121 | 0.260 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 140 | 0.250 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2008 | 117 | 0.250 |
Why?
|
| Hypertension, Malignant | 2 | 2017 | 7 | 0.250 |
Why?
|
| Sick Leave | 2 | 2023 | 4 | 0.250 |
Why?
|
| Odds Ratio | 4 | 2021 | 1211 | 0.250 |
Why?
|
| Hospitals | 4 | 2024 | 435 | 0.250 |
Why?
|
| Databases, Factual | 7 | 2020 | 1240 | 0.240 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2026 | 8 | 0.240 |
Why?
|
| Recovery of Function | 4 | 2023 | 449 | 0.240 |
Why?
|
| Epidemiologic Research Design | 2 | 2016 | 7 | 0.240 |
Why?
|
| Health Resources | 2 | 2017 | 131 | 0.230 |
Why?
|
| Fibrosis | 2 | 2018 | 429 | 0.230 |
Why?
|
| Surveys and Questionnaires | 6 | 2026 | 4066 | 0.230 |
Why?
|
| Hyperkalemia | 2 | 2017 | 68 | 0.230 |
Why?
|
| Renin-Angiotensin System | 1 | 2026 | 104 | 0.220 |
Why?
|
| Internet | 2 | 2025 | 420 | 0.220 |
Why?
|
| Decision Making | 3 | 2022 | 726 | 0.220 |
Why?
|
| Hospital Mortality | 5 | 2020 | 1064 | 0.220 |
Why?
|
| Quality Improvement | 3 | 2021 | 722 | 0.220 |
Why?
|
| Perioperative Care | 3 | 2022 | 217 | 0.210 |
Why?
|
| Survival Analysis | 3 | 2020 | 1483 | 0.210 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 1410 | 0.210 |
Why?
|
| Patient Preference | 2 | 2023 | 151 | 0.210 |
Why?
|
| Mobile Applications | 1 | 2025 | 114 | 0.200 |
Why?
|
| Case-Control Studies | 2 | 2021 | 3359 | 0.200 |
Why?
|
| Age Factors | 6 | 2025 | 2825 | 0.200 |
Why?
|
| Anticoagulants | 3 | 2023 | 605 | 0.200 |
Why?
|
| Bacteremia | 1 | 2008 | 446 | 0.200 |
Why?
|
| Nephrologists | 1 | 2023 | 19 | 0.200 |
Why?
|
| Global Health | 3 | 2018 | 626 | 0.200 |
Why?
|
| Stroke | 3 | 2023 | 1061 | 0.190 |
Why?
|
| Interviews as Topic | 2 | 2026 | 466 | 0.190 |
Why?
|
| Vascular Access Devices | 2 | 2013 | 31 | 0.190 |
Why?
|
| Insulins | 1 | 2022 | 18 | 0.190 |
Why?
|
| Multimorbidity | 1 | 2022 | 23 | 0.180 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2023 | 71 | 0.180 |
Why?
|
| Cardiac Rehabilitation | 1 | 2022 | 29 | 0.180 |
Why?
|
| Hemorrhage | 4 | 2023 | 487 | 0.180 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 294 | 0.180 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2022 | 60 | 0.170 |
Why?
|
| Heart | 1 | 2026 | 650 | 0.170 |
Why?
|
| Risk | 4 | 2019 | 726 | 0.170 |
Why?
|
| Image Enhancement | 2 | 2021 | 159 | 0.170 |
Why?
|
| Angina, Stable | 1 | 2020 | 8 | 0.170 |
Why?
|
| Hypoglycemia | 1 | 2022 | 190 | 0.170 |
Why?
|
| Brain Ischemia | 1 | 2023 | 266 | 0.170 |
Why?
|
| Physician-Patient Relations | 2 | 2024 | 441 | 0.170 |
Why?
|
| Nitrogen Dioxide | 1 | 2020 | 25 | 0.160 |
Why?
|
| Polysomnography | 3 | 2016 | 153 | 0.160 |
Why?
|
| Population Dynamics | 1 | 2020 | 30 | 0.160 |
Why?
|
| Software | 1 | 2025 | 733 | 0.160 |
Why?
|
| Patient Safety | 3 | 2021 | 443 | 0.150 |
Why?
|
| Air Pollution | 1 | 2020 | 79 | 0.150 |
Why?
|
| Psychometrics | 4 | 2025 | 678 | 0.150 |
Why?
|
| Propensity Score | 3 | 2020 | 271 | 0.150 |
Why?
|
| Organ Dysfunction Scores | 1 | 2019 | 53 | 0.150 |
Why?
|
| Young Adult | 8 | 2024 | 10103 | 0.150 |
Why?
|
| Intraoperative Period | 1 | 2019 | 63 | 0.150 |
Why?
|
| Comparative Effectiveness Research | 2 | 2016 | 73 | 0.150 |
Why?
|
| Professional-Patient Relations | 1 | 2020 | 92 | 0.150 |
Why?
|
| Social Support | 2 | 2019 | 370 | 0.150 |
Why?
|
| Sepsis | 1 | 2023 | 493 | 0.150 |
Why?
|
| Patient Selection | 2 | 2014 | 729 | 0.140 |
Why?
|
| Colonic Polyps | 1 | 2020 | 82 | 0.140 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 236 | 0.140 |
Why?
|
| Hospital Costs | 1 | 2020 | 188 | 0.140 |
Why?
|
| Dipeptidases | 1 | 2018 | 15 | 0.140 |
Why?
|
| Algorithms | 2 | 2023 | 1680 | 0.140 |
Why?
|
| Immunologic Surveillance | 1 | 2018 | 14 | 0.140 |
Why?
|
| Estradiol | 1 | 2020 | 460 | 0.140 |
Why?
|
| Curcumin | 1 | 2018 | 41 | 0.140 |
Why?
|
| Myocardial Revascularization | 1 | 2018 | 100 | 0.140 |
Why?
|
| Survival Rate | 6 | 2020 | 2114 | 0.140 |
Why?
|
| Estrogens | 1 | 2020 | 434 | 0.140 |
Why?
|
| Colonoscopy | 1 | 2020 | 243 | 0.130 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 176 | 0.130 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 239 | 0.130 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2020 | 267 | 0.130 |
Why?
|
| Hepatectomy | 1 | 2018 | 131 | 0.130 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 179 | 0.130 |
Why?
|
| Gadolinium | 1 | 2018 | 110 | 0.130 |
Why?
|
| Survivors | 2 | 2023 | 344 | 0.130 |
Why?
|
| Environmental Exposure | 1 | 2020 | 298 | 0.130 |
Why?
|
| Medicine | 1 | 2018 | 101 | 0.130 |
Why?
|
| Health Services, Indigenous | 1 | 2017 | 5 | 0.130 |
Why?
|
| Elective Surgical Procedures | 2 | 2018 | 162 | 0.130 |
Why?
|
| Primary Health Care | 1 | 2023 | 775 | 0.130 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2017 | 50 | 0.130 |
Why?
|
| Dementia | 1 | 2022 | 436 | 0.130 |
Why?
|
| Epilepsy | 1 | 2024 | 876 | 0.120 |
Why?
|
| Indians, North American | 1 | 2017 | 71 | 0.120 |
Why?
|
| Pyrenes | 1 | 2016 | 7 | 0.120 |
Why?
|
| Postmenopause | 1 | 2017 | 137 | 0.120 |
Why?
|
| Rural Health Services | 1 | 2017 | 41 | 0.120 |
Why?
|
| Obesity Hypoventilation Syndrome | 1 | 2016 | 4 | 0.120 |
Why?
|
| Health Promotion | 1 | 2020 | 422 | 0.120 |
Why?
|
| Catheterization | 1 | 2017 | 226 | 0.120 |
Why?
|
| Mass Screening | 2 | 2024 | 822 | 0.120 |
Why?
|
| Prospective Studies | 6 | 2020 | 6459 | 0.120 |
Why?
|
| Early Medical Intervention | 1 | 2016 | 32 | 0.110 |
Why?
|
| Myocardial Ischemia | 1 | 2018 | 307 | 0.110 |
Why?
|
| Aortic Valve | 1 | 2019 | 455 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2016 | 82 | 0.110 |
Why?
|
| Self Report | 1 | 2019 | 554 | 0.110 |
Why?
|
| Treatment Failure | 1 | 2016 | 351 | 0.110 |
Why?
|
| Catheter-Related Infections | 2 | 2017 | 146 | 0.110 |
Why?
|
| Lymphoma | 1 | 2018 | 327 | 0.110 |
Why?
|
| National Health Programs | 1 | 2015 | 20 | 0.110 |
Why?
|
| Watchful Waiting | 1 | 2016 | 73 | 0.110 |
Why?
|
| Constriction, Pathologic | 1 | 2016 | 221 | 0.110 |
Why?
|
| Vitamin D | 1 | 2016 | 194 | 0.110 |
Why?
|
| Thrombosis | 2 | 2017 | 499 | 0.110 |
Why?
|
| Pneumothorax | 1 | 2015 | 82 | 0.100 |
Why?
|
| Cancer Survivors | 1 | 2018 | 283 | 0.100 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2018 | 372 | 0.100 |
Why?
|
| Publication Bias | 1 | 2013 | 17 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2017 | 562 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2015 | 297 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2016 | 463 | 0.100 |
Why?
|
| Population Surveillance | 1 | 2015 | 396 | 0.100 |
Why?
|
| Caregivers | 1 | 2019 | 598 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 464 | 0.090 |
Why?
|
| Delphi Technique | 2 | 2025 | 283 | 0.090 |
Why?
|
| Cardiology | 1 | 2018 | 514 | 0.090 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 1224 | 0.090 |
Why?
|
| Oxygen | 1 | 2015 | 548 | 0.090 |
Why?
|
| Radiography | 1 | 2014 | 743 | 0.090 |
Why?
|
| Markov Chains | 2 | 2026 | 101 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 226 | 0.090 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 66 | 0.090 |
Why?
|
| United States | 4 | 2018 | 12072 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2026 | 1490 | 0.080 |
Why?
|
| Ambulatory Care | 3 | 2023 | 401 | 0.080 |
Why?
|
| Poisson Distribution | 1 | 2010 | 50 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2013 | 214 | 0.080 |
Why?
|
| Creatine | 1 | 2010 | 37 | 0.080 |
Why?
|
| Biomarkers | 5 | 2019 | 3385 | 0.080 |
Why?
|
| Information Services | 1 | 2009 | 23 | 0.080 |
Why?
|
| Consensus | 2 | 2025 | 512 | 0.080 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 604 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3763 | 0.070 |
Why?
|
| Adolescent | 4 | 2021 | 20987 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2018 | 982 | 0.070 |
Why?
|
| Ascorbic Acid | 1 | 2009 | 72 | 0.070 |
Why?
|
| Ontario | 2 | 2023 | 85 | 0.070 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 185 | 0.070 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2017 | 767 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2024 | 314 | 0.070 |
Why?
|
| ROC Curve | 2 | 2022 | 613 | 0.070 |
Why?
|
| Research Design | 2 | 2025 | 716 | 0.070 |
Why?
|
| Administration, Topical | 1 | 2008 | 130 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 1373 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1882 | 0.070 |
Why?
|
| Mycophenolic Acid | 1 | 2007 | 54 | 0.060 |
Why?
|
| Lupus Nephritis | 1 | 2007 | 43 | 0.060 |
Why?
|
| Vancomycin Resistance | 1 | 2026 | 24 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2020 | 761 | 0.060 |
Why?
|
| Urinalysis | 2 | 2020 | 72 | 0.060 |
Why?
|
| Anemia | 1 | 2009 | 354 | 0.060 |
Why?
|
| Tertiary Care Centers | 1 | 2026 | 263 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2008 | 401 | 0.050 |
Why?
|
| Drug Prescriptions | 2 | 2018 | 237 | 0.050 |
Why?
|
| User-Computer Interface | 1 | 2025 | 164 | 0.050 |
Why?
|
| Vancomycin | 1 | 2026 | 226 | 0.050 |
Why?
|
| Prevalence | 3 | 2017 | 2701 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2025 | 331 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 555 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 663 | 0.050 |
Why?
|
| United Kingdom | 2 | 2014 | 267 | 0.050 |
Why?
|
| Hypovolemia | 1 | 2022 | 12 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2025 | 483 | 0.050 |
Why?
|
| Logistic Models | 2 | 2020 | 1797 | 0.050 |
Why?
|
| Pharmacists | 1 | 2023 | 104 | 0.050 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2022 | 129 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2022 | 96 | 0.040 |
Why?
|
| Hemoglobins | 2 | 2016 | 286 | 0.040 |
Why?
|
| Sex Factors | 1 | 2026 | 1356 | 0.040 |
Why?
|
| Inventions | 1 | 2021 | 19 | 0.040 |
Why?
|
| Exercise Test | 1 | 2022 | 239 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2022 | 211 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2019 | 1717 | 0.040 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2020 | 16 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2021 | 76 | 0.040 |
Why?
|
| Health Planning | 1 | 2020 | 16 | 0.040 |
Why?
|
| Erythrocyte Count | 1 | 2020 | 23 | 0.040 |
Why?
|
| Erythrocyte Indices | 1 | 2020 | 12 | 0.040 |
Why?
|
| Chlorides | 1 | 2020 | 97 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2021 | 230 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 139 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 237 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 258 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 246 | 0.040 |
Why?
|
| APACHE | 1 | 2019 | 55 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2020 | 69 | 0.040 |
Why?
|
| Albumins | 1 | 2020 | 87 | 0.040 |
Why?
|
| Potassium | 1 | 2020 | 263 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2019 | 304 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 280 | 0.040 |
Why?
|
| Dyspnea | 1 | 2020 | 159 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2019 | 59 | 0.040 |
Why?
|
| Natriuretic Peptide, C-Type | 1 | 2018 | 15 | 0.040 |
Why?
|
| Pacemaker, Artificial | 1 | 2021 | 193 | 0.040 |
Why?
|
| Defibrillators, Implantable | 1 | 2021 | 215 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 43 | 0.030 |
Why?
|
| Phagocytes | 1 | 2018 | 25 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2022 | 564 | 0.030 |
Why?
|
| Interleukin-18 | 1 | 2018 | 75 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2022 | 1117 | 0.030 |
Why?
|
| Egypt | 1 | 2017 | 33 | 0.030 |
Why?
|
| Radiologists | 1 | 2018 | 53 | 0.030 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2017 | 17 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 1618 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2018 | 110 | 0.030 |
Why?
|
| Australasia | 1 | 2017 | 5 | 0.030 |
Why?
|
| Catheter Obstruction | 1 | 2017 | 8 | 0.030 |
Why?
|
| Manitoba | 1 | 2017 | 3 | 0.030 |
Why?
|
| Aviation | 1 | 2017 | 4 | 0.030 |
Why?
|
| Motor Vehicles | 1 | 2017 | 10 | 0.030 |
Why?
|
| Perception | 1 | 2019 | 231 | 0.030 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2017 | 51 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2020 | 229 | 0.030 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2018 | 127 | 0.030 |
Why?
|
| Models, Economic | 1 | 2017 | 59 | 0.030 |
Why?
|
| Leukocytes | 1 | 2018 | 205 | 0.030 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 33 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2017 | 80 | 0.030 |
Why?
|
| Affect | 1 | 2018 | 159 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2017 | 169 | 0.030 |
Why?
|
| Inflammasomes | 1 | 2018 | 154 | 0.030 |
Why?
|
| North America | 1 | 2017 | 255 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 129 | 0.030 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2016 | 8 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2017 | 195 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 711 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 365 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 450 | 0.030 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2015 | 32 | 0.030 |
Why?
|
| Palliative Care | 1 | 2020 | 443 | 0.030 |
Why?
|
| Vascular Patency | 1 | 2016 | 185 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2019 | 460 | 0.030 |
Why?
|
| Emotions | 1 | 2018 | 350 | 0.030 |
Why?
|
| Emergencies | 1 | 2016 | 171 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1626 | 0.030 |
Why?
|
| Prosthesis-Related Infections | 1 | 2017 | 197 | 0.030 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2015 | 88 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2015 | 222 | 0.030 |
Why?
|
| Arteries | 1 | 2015 | 208 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 95 | 0.030 |
Why?
|
| Premedication | 1 | 2014 | 39 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 645 | 0.030 |
Why?
|
| Reoperation | 1 | 2017 | 818 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2017 | 674 | 0.030 |
Why?
|
| Wrist Injuries | 1 | 2013 | 7 | 0.020 |
Why?
|
| Animals | 2 | 2018 | 33912 | 0.020 |
Why?
|
| Rosuvastatin Calcium | 1 | 2013 | 42 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 216 | 0.020 |
Why?
|
| Fluorobenzenes | 1 | 2013 | 39 | 0.020 |
Why?
|
| Heptanoic Acids | 1 | 2013 | 79 | 0.020 |
Why?
|
| Spinal Fractures | 1 | 2013 | 48 | 0.020 |
Why?
|
| Simvastatin | 1 | 2013 | 76 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 272 | 0.020 |
Why?
|
| Hip Fractures | 1 | 2013 | 64 | 0.020 |
Why?
|
| Cognition | 1 | 2018 | 829 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1216 | 0.020 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2016 | 425 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 501 | 0.020 |
Why?
|
| Physicians | 1 | 2018 | 635 | 0.020 |
Why?
|
| Reagent Strips | 1 | 2011 | 12 | 0.020 |
Why?
|
| Pyrroles | 1 | 2013 | 188 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 732 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2011 | 111 | 0.020 |
Why?
|
| Multiple Organ Failure | 1 | 2012 | 145 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2013 | 296 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 230 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2018 | 3819 | 0.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2011 | 161 | 0.020 |
Why?
|
| Heart Rate | 1 | 2013 | 577 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 2085 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2014 | 385 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2013 | 446 | 0.020 |
Why?
|
| Outpatients | 1 | 2011 | 262 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 825 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 4738 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2009 | 141 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 650 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 1489 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 4697 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2015 | 910 | 0.020 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 326 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 3829 | 0.010 |
Why?
|
| Child | 1 | 2022 | 26341 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 18301 | 0.010 |
Why?
|